GlaxoSmithKline/£GSK

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About GlaxoSmithKline

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Ticker

£GSK
Sector

Primary listing

LSE

Employees

68,629

GlaxoSmithKline Metrics

BasicAdvanced
£65B
19.63
£0.83
0.29
£0.62
3.82%

What the Analysts think about GlaxoSmithKline

Analyst ratings (Buy, Hold, Sell) for GlaxoSmithKline stock.

Bulls say / Bears say

GSK’s Specialty Medicines segment fueled a 6% rise in Q2 2025 sales at constant exchange rates to £8 billion, as strong double-digit gains in respiratory, immunology, oncology, and HIV products prompted the company to project full-year sales and profit at the upper end of its guidance (Reuters).
In January 2025, GSK acquired U.S. biotech company IDRx for up to $1.15 billion, gaining global rights to a range of gastrointestinal cancer assets and strengthening its oncology pipeline through focused business development (Reuters).
In February 2025, GSK announced a £2 billion share buyback and raised its 2031 sales goal to over £40 billion, crediting this upgrade to substantial late-stage pipeline progress—especially in oncology—which underscores management’s confidence in the company’s long-term growth outlook (Bloomberg).
GSK’s vaccine division continues to struggle, with its RSV vaccine Arexvy bringing in just £0.1 billion in Q1 2025—a 57% year-over-year drop—which contributed to a 6% decrease in overall vaccine sales and highlights ongoing weakness in this business segment (Reuters).
Analysts predict GSK will reach only £34 billion in revenue by 2031—15% under management’s £40 billion goal—showing significant doubt about the company’s ability to achieve its stated growth targets without major breakthroughs (Reuters Breakingviews).
GSK’s leading HIV drug, dolutegravir, will lose patent protection from 2028 in the U.S., putting nearly 20% of the company’s current revenue at risk and raising the threat of a significant revenue gap if upcoming products fail to perform or are delayed (Reuters Breakingviews).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

GlaxoSmithKline Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GlaxoSmithKline Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £GSK

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy GlaxoSmithKline stock | £GSK Share Price | Lightyear